ArticleEuropean journal of neurology2025
Impact of Erenumab on Comorbid Depression, Anxiety, and Sleep Quality in Migraine: A Registry for Migraine (REFORM) Study.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rimegepant for vestibular and cochlear symptoms associated with vertigo in a real-world retrospective study.iScience · 2026Article
- Impact of Erenumab on Comorbid Depression, Anxiety, and Sleep Quality in Migraine: A Registry for Migraine (REFORM) Study.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMigraine frequently co-exists with psychiatric comorbidities, including anxiety, depression, and sleep disturbances. Erenumab, a monoclonal antibody targeting the calcitonin gene-related peptide receptor, effectively reduces migraine frequency, but its impact on psychiatric symptoms remains unclear. This study evaluated the effects of erenumab on anxiety, depression, and sleep quality in individuals with migraine.
methodsThis non-randomized, single-arm, open-label trial was conducted within the prospective Registry for Migraine (REFORM). Adults with migraine received 140-mg erenumab monthly for 24 weeks. Anxiety, depression, and sleep-related symptoms were evaluated at baseline, Week 12, and Week 24 using the hospital anxiety and depression scale (HADS) and the Pittsburgh sleep quality index (PSQI). Participants were stratified by treatment response during Weeks 13-24 (≥ 50% reduction in monthly migraine days) and psychiatric history.
resultsAmong 675 participants completing ≥ 12 weeks, the proportion at risk for anxiety decreased from 30.1% (196/651) at baseline to 22.8% (136/597) at Week 24, and for depression from 24.9% (162/651) to 18.3% (109/597, both p < 0.001). Poor sleep quality decreased from 66.1% (429/649) to 56.3% (333/592, p < 0.001). Only ≥ 50% responders (300/582, 51.5%) achieved significant improvements in anxiety, depression, and sleep-related symptoms (All p < 0.001), whereas < 50% responders did not improve significantly (All p > 0.05). Improvements were significant in both subgroups with and without psychiatric history (All p < 0.001).
conclusionsErenumab treatment is associated with improvement in anxiety, depression, and sleep-related symptoms, specifically in treatment responders. These benefits appear mediated by migraine control rather than direct pharmacological effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.